$ERAS

Erasca (ERAS) shares declined after terminating its COO as part of a strategic initiative to advance its cancer drug programs. The move aims to support the development and future commercialization of its RAS-targeting therapies, according to the company.

Erasca, Inc. (ERAS) will terminate its Chief Operating Officer, Nicholas Chetwyn, effective November 2, 2026, as part of a leadership realignment. Responsibilities will transition to other members of the leadership team.

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 15, 2026, Erasca, Inc. (the Company) decided to realign its leadership responsibilities to support the developme

On 8 October 2026, Haemonetics (HAE) rose 17.46% to $119.47, while Applied Optoelectronics (AAOI) fell 13.58% to $105.90. Other notable movers included Veradermics (MANE), Securitize (SECZ), The Vita Coco Company (COCO), Erasca (ERAS), MaxLinear (MXL), argenx (ARGX), EquipmentShare.com (EQPT), and Hut 8 (HUT).

Erasca (ERAS) received FDA Fast Track Designation for ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic cancer. The designation allows for accelerated regulatory review. In a Phase 1 trial, ERAS-0015 showed a 57% response rate in pancreatic cancer patients. The company plans to initiate pivotal trials in 2027. Q2 2026 R&D expenses rose to $35.9M, and net loss widened to $44.1M. Erasca raised $632.5M in July 2026, leaving it with $384.3M in cash.

Erasca, Inc. (ERAS) shares dropped nearly 40% after-hours following a treatment-related death in a Phase 1 study of its cancer therapy ERAS-0015, despite positive early tumor response rates. The patient, a 66-year-old with pancreatic cancer, died after developing pneumonitis. The company reported strong response rates in lung and pancreatic cancers and plans to advance to expansion studies. Additionally, Erasca faces patent infringement allegations from Revolution Medicines regarding ERAS-0015.

Erasca (ERAS) reported a wider net loss of $287.223M in Q2 2026 and appointed Charles S. Fuchs as R&D president. The stock trades at $18.10, with 90-day and YTD returns of 55.97% and 404.18%, respectively. Despite a high P/B ratio of 17.5x, the company has no revenue and forecasts losses for the next three years. The article questions whether the stock is overvalued.

Erasca (NasdaqGS:ERAS) reported wider Q2 and first-half 2026 net losses, filed a US$112.34 million ESOP-related shelf registration, disclosed a US securities class action tied to its ERAS-0015 program, and appointed Charles S. Fuchs as president of R&D. The piece discusses how these items affect the ERAS-0015 investment narrative and cites fair value estimates from US$4.96 to US$23.30.

Erasca raised about $891.3M gross across two 2026 public offerings, including $632.5M in an upsized July offering and $258.8M in an upsized January offering. Cash was $384.3M as of June 30. The company says proceeds will fund accelerated development of ERAS-0015 and three potentially registration-enabling studies starting 2027-2028.

Analyst estimates for Erasca, Inc. show the average 12-month price target increased from $22.55 to $22.73, with a range of $18 to $30, according to 11 analysts. Based on the Aug. 11 close, the target suggests about 24% upside. The consensus rating remains “Buy” with 9 Buys, 2 Holds, and 0 Sells.